Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.

被引：0
|
作者：
Bai, Chunmei
Xu, Jianming
Shen, Lin
Li, Jie
Zhou, Zhiwei
Chi, Yihebali
Li, Zhiping
Xu, Nong
Li, Enxiao
Liu, Tianshu
Bai, Yuxian
Yuan, Ying
Li, Xingya
Wang, Xiuwen
Chen, Jia
Ying, Jieer
Li, Jing
Fan, Songhua
Peng, Mengye
Su, Weiguo
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China
[6] West China Hosp, Chengdu, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[8] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China
[9] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[10] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[11] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[12] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[13] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[14] Jiangsu Canc Hosp, Nanjing, Peoples R China
[15] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[16] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[17] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4613
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Health-Related Quality-of-Life Analysis of Surufatinib Versus Placebo for Advanced Neuroendocrine Tumors: Pooled Results From Two Phase 3 Studies (SANET-p and SANET-ep)
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    PANCREAS, 2022, 51 (03) : E39 - E39
  • [2] Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 1 - 9
  • [3] Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
    Xu, J.
    Shen, L.
    Zhou, Z.
    Li, J.
    Bai, C.
    Chi, Y.
    Li, Z.
    Xu, N.
    Jia, R.
    Li, E.
    Liu, T.
    Bai, Y.
    Yuan, Y.
    Li, X.
    Wang, X.
    Chen, J.
    Ying, J.
    Li, J.
    Fan, S.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30 : 911 - 911
  • [4] Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
    Xu, Jianming
    Shen, Lin
    Zhou, Zhiwei
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Ying, Jieer
    Yu, Xianjun
    Qin, Shukui
    Yuan, Xianglin
    Zhang, Tao
    Deng, Yanhong
    Xiu, Dianrong
    Cheng, Ying
    Tao, Min
    Jia, Ru
    Wang, Wei
    Li, Jing
    Fan, Songhua
    Peng, Mengye
    Su, Weiguo
    LANCET ONCOLOGY, 2020, 21 (11): : 1500 - 1512
  • [5] 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 247 - 248
  • [6] Subgroup Analysis by Ki-67 and Primary Tumor Origins of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Extrapancreatic Neuroendocrine Tumors (SANET-ep)
    Zhou, Zhiwei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Wang, Wei
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    PANCREAS, 2022, 51 (03) : E43 - E43
  • [7] Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
    Zhou, Z.
    Xu, J.
    Shen, L.
    Li, J.
    Bai, C.
    Chi, Y.
    Li, Z.
    Xu, N.
    Jia, R.
    Li, E.
    Liu, T.
    Bai, Y.
    Yuan, Y.
    Li, X.
    Wang, X.
    Chen, J.
    Wang, W.
    Li, J.
    He, J.
    Su, W.
    ANNALS OF ONCOLOGY, 2020, 31 : S775 - S775
  • [8] Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
    Li, J.
    Xu, J.
    Zhou, Z.
    Bai, C.
    Chi, Y.
    Li, Z.
    Xu, N.
    Li, E.
    Liu, T.
    Bai, Y.
    Guan, S.
    Shen, L.
    NEUROENDOCRINOLOGY, 2020, 110 : 213 - 213
  • [9] Health-related quality of life results from the phase III CheckMate 067 study
    Schadendorf, Dirk
    Larkin, James
    Wolchok, Jedd
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher
    Wagstaff, John
    Callahan, Margaret K.
    Postow, Michael A.
    Smylie, Michael
    Ferrucci, Pier Francesco
    Dummer, Reinhard
    Hill, Andrew
    Taylor, Fiona
    Sabater, Javier
    Walker, Dana
    Kotapati, Srividya
    Abernethy, Amy
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2017, 82 : 80 - 91
  • [10] Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors
    Di Costanzo, Fabrizio
    Napolitano, Fabiana
    Salomone, Fabio
    Amato, Anna Rita
    Alberico, Gennaro
    Migliaccio, Fortuna
    Pecoraro, Giovanna
    Marra, Annachiara
    Crocetto, Felice
    Ruffo, Antonio
    Scagliarini, Sarah
    Rossetti, Sabrina
    Puglia, Livio
    Di Napoli, Marilena
    Bianco, Roberto
    Servetto, Alberto
    Formisano, Luigi
    CANCERS, 2023, 15 (23)
12345